Dr. Victoria Hale is a global health social entrepreneur. She has founded and run two nonprofit pharmaceutical companies, OneWorld Health, the first nonprofit pharmaceutical company in the US (2000), and Medicines360 (2009). She and her companies developed a new cure for visceral leishmaniasis, developed a platform technology to reduce the cost of artemisinin malaria drugs by more than 10-fold, and developed an FDA-approved hormonal IUD (intrauterine device). Dr. Hale established her expertise in all stages of drug development at the US Food and Drug Administration (FDA), and at Genentech. She earned her PhD in Pharmaceutical Chemistry from the University of California San Francisco (UCSF), where she presently maintains an Adjunct Associate Professorship in the Department of Bioengineering & Therapeutic Sciences. She was elected to membership in the US National Academy Medicine, and was granted the MacArthur “Genius” Award. Dr. Hale is internationally recognized as a senior social entrepreneur by the Skoll Foundation, Schwab Foundation, and Ashoka. The Economist named her the recipient of its Social and Economic Innovation Award. Dr Hale's present focus is in infectious disease, reproductive health and oncology.